Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strata Skin SciencesSSKN Debt-to-Equity is 5.59 as of Dec. 2025, which is 1065% above its 10-year median of 0.48. The stock has 4 warning signs investors should review. Among 697 Medical Devices & Instruments companies, Strata Skin Sciences ranks worse than 97.85% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Strata Skin Sciences's Debt-to-Equity or its related term are showing as below:
SSKN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.24 Med: 0.48 Max: 5.59
Current: 5.59
During the past 13 years, the highest Debt-to-Equity Ratio of Strata Skin Sciences was 5.59. The lowest was 0.24. And the median was 0.48.
SSKN's Debt-to-Equity is ranked worse than 97.85% of 697
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs SSKN: 5.59
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Strata Skin Sciences Debt-to-Equity Related Terms
Strata Skin Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Strata Skin Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Skin Sciences Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Strata Skin Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Skin Sciences (SSKN) has a Debt-to-Equity of 5.59 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Strata Skin Sciences and its competitors. This is 1065% above median its historical median of 0.48. Over the past decade, Strata Skin Sciences' Debt-to-Equity has ranged from 0.24 to 5.59. According to the industry distribution chart, Strata Skin Sciences ranks #682 out of 697 companies in the Medical Devices & Instruments industry, placing it in the top 97.8%.
Is Strata Skin Sciences' Debt-to-Equity too high?
Strata Skin Sciences' current Debt-to-Equity of 5.59 is 1065% above median its 10-year median of 0.48. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 5.59. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Strata Skin Sciences' value of 5.59 is 2330.4% above this industry median. Based on the distribution chart, Strata Skin Sciences ranks #682 out of 697 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Strata Skin Sciences' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #682 out of 697 companies for Debt-to-Equity. This places Strata Skin Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Strata Skin Sciences' value of 5.59 is 2330.4% above this benchmark. Historically, Strata Skin Sciences' own Debt-to-Equity has ranged from 0.24 to 5.59 over the past decade. While the company's 10-year median is 0.48 vs. the industry median of 0.23, Strata Skin Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Skin Sciences's current Debt-to-Equity of 5.59 is 2330.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Strata Skin Sciences and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Skin Sciences's current Debt-to-Equity is 5.59, which is 1065% above median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Based on GuruFocus' analysis, Strata Skin Sciences (SSKN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.00, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Debt-to-Equity is 5.59, which is 1065% above median its 10-year median of 0.48 and 2330.4% above the Medical Devices & Instruments industry median of 0.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Strata Skin Sciences (SSKN), the current Debt-to-Equity is 5.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SSKN has been successfully added to your 
